Date:8/20/2012

Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (13) our dependence on third-party vendors; and (14) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan.  These and other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2011.Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe DiazAngeion Corporation

Lytham Partners, LLCChief Executive Officer and President

(602) 889-9700(651) 484-4874

angn@lythampartners.com 

'/>"/>

SOURCE Angeion Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
2. Angeion Selects Hendrik Struik for Board of Directors
3. VWR Funding, Inc. Announces Proposed Offering Of Senior Notes
4. VWR Funding, Inc. Announces Tender Offer Of Existing PIK Toggle Notes
5. Bausch + Lomb Announces Final Results for Its Previously Announced Tender Offer for Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3, U07190AA6 and 071707AP8)
6. BioDelivery Sciences Announces Completion of Enrollment in Pivotal Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone
7. ShangPharma Announces Second Quarter 2012 Results
8. Nectid Announces Initiation Of Clinical Development Of Autism And Pain Drugs
9. Apexigen Announces the Filing of an IND by its Partner, 3SBio
10. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
11. Perrigo Company Announces Quarterly Dividend